Transcatheter mitral valve repair for functional mitral regurgitation: Evaluating the evidence.


Journal

The Journal of thoracic and cardiovascular surgery
ISSN: 1097-685X
Titre abrégé: J Thorac Cardiovasc Surg
Pays: United States
ID NLM: 0376343

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 12 12 2019
revised: 06 02 2020
accepted: 17 02 2020
pubmed: 4 5 2020
medline: 3 11 2021
entrez: 4 5 2020
Statut: ppublish

Résumé

Two trials (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation Trial and Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation Trial) were published in 2018 evaluating the effectiveness and safety of transcatheter repair for patients with heart failure with significant functional mitral regurgitation, which yielded different results. This article reviews the strength of the evidence, differences in trial designs, ethical and implementation implications, and delineates future research needs to help guide the appropriate dissemination of transcatheter repair for functional patients with mitral regurgitation. The National Heart, Lung, and Blood Institute convened a workshop of interdisciplinary experts to address these objectives. Transcatheter repair of functional mitral regurgitation can provide significant benefits in terms of heart failure hospitalizations, survival, and quality of life when appropriate heart failure candidates with moderate to severe or severe mitral regurgitation while on optimal guideline-directed medical therapy can be identified. Key ingredients for success are preoperative evaluation and management and postoperative care by an interdisciplinary heart team. Given the discordance observed between trials, ongoing innovation in patient management, and potential expansion of indications for use, the evidence base must be expanded to optimize appropriate implementation of this complex therapy. This will require more complete capture of outcome data in real-world settings for all eligible candidates whether or not they receive this therapy. Inevitably, the indications for use of this therapy will expand, as will the devices and therapeutic approaches for this population, necessitating the study of comparative effectiveness through randomized trials or observational studies. Moreover, given the substantial variations in care delivery, conducting implementation research to delineate characteristics of the optimal care model would be of benefit.

Identifiants

pubmed: 32359794
pii: S0022-5223(20)30630-9
doi: 10.1016/j.jtcvs.2020.02.132
pmc: PMC7935447
mid: NIHMS1675742
pii:
doi:

Types de publication

Consensus Development Conference, NIH Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1504-1511

Subventions

Organisme : NHLBI NIH HHS
ID : U01 HL088942
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Références

J Am Coll Cardiol. 2019 May 7;73(17):2123-2132
pubmed: 30894288
N Engl J Med. 2014 Dec 4;371(23):2178-88
pubmed: 25405390
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
N Engl J Med. 2018 Dec 13;379(24):2307-2318
pubmed: 30280640
JACC Cardiovasc Imaging. 2019 Feb;12(2):353-362
pubmed: 30553663
J Am Soc Echocardiogr. 2017 Apr;30(4):303-371
pubmed: 28314623
Eur J Heart Fail. 2019 Dec;21(12):1619-1627
pubmed: 31476260
J Am Coll Cardiol. 2014 Dec 30;64(25):2792-801
pubmed: 25541133
JACC Cardiovasc Interv. 2019 Jul 22;12(14):1342-1352
pubmed: 31320029
N Engl J Med. 2018 Dec 13;379(24):2297-2306
pubmed: 30145927
JACC Cardiovasc Interv. 2019 Jul 22;12(14):1353-1355
pubmed: 31320030
J Thorac Cardiovasc Surg. 2019 Jul;158(1):76-81
pubmed: 30773386
JACC Heart Fail. 2019 Jun;7(6):522-526
pubmed: 31078477
J Am Coll Cardiol. 2020 Jul 7;76(1):96-117
pubmed: 31857196
Am Heart J. 2018 Nov;205:1-11
pubmed: 30134187
N Engl J Med. 2018 Dec 13;379(24):2374-2376
pubmed: 30575469
N Engl J Med. 2014 Jan 2;370(1):23-32
pubmed: 24245543

Auteurs

Annetine C Gelijns (AC)

Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, NY. Electronic address: Annetine.gelijns@mssm.edu.

Alan J Moskowitz (AJ)

Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, NY.

Patrick T O'Gara (PT)

Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass.

Gennaro Giustino (G)

Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, NY.

Michael J Mack (MJ)

Cardiothoracic Surgery, Baylor Research Institute, Baylor Scott & White Health, Plano, Tex.

Donna M Mancini (DM)

Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, NY.

Emilia Bagiella (E)

Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, NY.

Judy Hung (J)

Division of Cardiology, Massachusetts General Hospital, Boston, Mass.

Gorav Ailawadi (G)

Section of Adult Cardiac Surgery, University of Virginia, Charlottesville, Va.

Martin B Leon (MB)

Center for Interventional Vascular Therapy, Columbia University Medical Center/New York-Presbyterian Hospital and Cardiovascular Research Foundation, New York, NY.

Michael A Acker (MA)

Cardiovascular Surgery, Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pa.

John H Alexander (JH)

Division of Cardiology, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Neal W Dickert (NW)

Division of Cardiology, Emory University School of Medicine, Atlanta, Ga.

Wendy C Taddei-Peters (WC)

Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Md.

Marissa A Miller (MA)

Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Md.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH